To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
MPM nets big return on Idenix exit
The US life sciences investor has sold the hepatitis and HIV treatment company to Novartis in a deal that values the business at up to $612m.
